Anyone have an opinion about FDA's decision to forego an advisory panel meeting regarding Sarepta's Gene therapy SRP-9001 for Duchenne muscular dystrophy (DMD)?
https://www.fiercebiotech.com/biotech/fda-skips-ad-comm-sareptas-dmd-gene-therapy-candidate-sets-decision-date
It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Anyone have an opinion about FDA's decision to forego an...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.040(3.76%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.09 | $1.03 | $7.869M | 7.571M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16411 | $1.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 3952 | 2 |
View Market Depth
| Last trade - 16.10pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.03 |
Change
-0.040 ( 3.65 %) |
||||
| Open | High | Low | Volume | ||
| $1.07 | $1.08 | $1.03 | 1907057 | ||
| Last updated 15.59pm 06/06/2024 ? | |||||
| MSB (ASX) Chart |